Download Xeloda (Breast Cancer) - Analysis and Forecasts to 2020 Brochure

Brochure
More information from http://www.researchandmarkets.com/reports/2114425/
Xeloda (Breast Cancer) - Analysis and Forecasts to 2020
Description:
Xeloda (Breast Cancer) – Analysis and Forecasts to 2020
Summary
GlobalData’s pharmaceuticals report, “Xeloda (Breast cancer) - Analysis and Forecasts to 2020” provides
Xeloda sales forecasts for US, EU5 and Japan. In addition, it covers detailed clinical assessment of the drug,
factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast
period (2002-2020). The report also includes information on Breast Cancer market. This report is built using
data and information sourced from GlobalData’s proprietary databases, primary and secondary research
using Company’s corporate website, SEC filings, investor presentations and featured press releases, both
from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's
team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Xeloda including sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Xeloda including efficacy, safety, pricing, competition and other details which influence
its sales potential
- Detailed sales forecasts from 2002-2020 for Xeloda in the seven major markets
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales
potential
- Make more informed business decisions from insightful and in-depth analysis of the drug’s performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Keywords
XELODA, Breast cancer, Capecitabine, Sales forecast, DNA synthesis Inhibitor, Phase III, Phase 3, Pipeline,
Competitors to Gemzar, Tykerb, Afatinib, Halaven and Omnitarg, Roche
Contents:
1
1
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Breast Cancer Market
2.2 Epidemiology
2.3 Etiology and Risk Factors
2.3.1 Age and Gender
2.3.2 Genetic Inheritance
2.3.3 Hormone Replacement Therapy
2.3.4 Radiation
2.3.5 Obesity
2.3.6 Alcohol Consumption
2.3.7 Late Child Birth
2.3.8 Use of Birth Control Pills
2.4 GlobalData Report Guidance
3 Breast Cancer: Market Characterization
3.1 Breast Cancer Market
3.2 Breast Cancer Market Forecasts and CAGR
3.3 Drivers of Breast Cancer Market
3.3.1 Breast Cancer: Most Frequent Cancer in Women
3.3.2 Increasing Breast Cancer Incidence Rate
3.3.3 Decreasing Breast Cancer Mortality Rate
3.3.4 High Survival Rates of Breast Cancer
4 Staging of Breast Cancer: Introduction
4.1 Distribution of Patients by Stages
4.1.1 Stages
5 Predictive Biomarker in the Treatment of Breast Cancer
6 Treatment Options of Breast Cancer
6.1 Stage 0 Breast Cancer
6.2 Early Stage Breast Cancer (Excluding Stage 0)
6.3 Metastatic Breast Cancer (MBC)
6.3.1 Endocrine Treatment: Adjuvant, First Line and Second Line
6.3.2 Cytotoxic Chemotherapy
6.3.3 Management of Patients with HER-2 Positive Patients
7 Xeloda
7.1 Introduction
7.2 Mechanism of Action
7.3 Clinical Studies
7.3.1 Breast Cancer Combination Therapy
7.3.2 Breast Cancer Monotherapy
7.4 Approval History of Xeloda
7.5 Factors Affecting Sales
7.5.1 High Efficacy of Xeloda in Combination with docetaxel
7.5.2 Patent Expiry of Competing Drugs
7.5.3 Additional Approval of Xeloda in Combination with Other Drugs in Breast Cancer
7.6 Drug Evaluation
7.6.1 Drug Risk Benefit Score
7.6.2 Intensity of Competition
7.7 Sales Forecasts
7.7.1 Target Patient Pool of Xeloda
7.7.2 Dosing
7.7.3 Market Penetration
7.7.4 Annual Cost of Therapy
7.7.5 Sales Projection of Xeloda
8 Appendix
8.1 Market Definitions
8.2 Abbreviations
8.3 Research Methodology
8.3.1 Coverage
8.3.2 Secondary Research
8.3.3 Forecasting
8.3.4 Number of Patients Approved to Take the Drug
8.3.5 Net Penetration of Drug
8.3.6 Net Annual Dosing
8.3.7 Annual Cost of Therapy
8.4 Drug Sales Estimates Model
8.5 Contact Us
8.6 Disclaimer
8.7 Sources
1.1 List of Tables
Table 1: Breast Cancer, Incidences and Mortality, By Country, 2008-2030
Table 2: Five-Year Relative Survival Rates, 2005, By Stages
Table 3: Efficacy of Xeloda and docetaxel Combination vs. docetaxel Monotherapy
Table 4: Response Rates in Breast Cancer Monotherapy with Xeloda
Table 5: Approval History of Xeloda
Table 6: Drug Risk Benefit Score of Xeloda
Table 7: Annual Cost of Therapy of Xeloda
Table 8: Xeloda, Breast Cancer, Global, Sales Estimates ($m), 2002–2020
Table 9: Xeloda, Breast Cancer, The US, Sales Estimates ($m), 2002–2020
Table 10: Xeloda, Breast Cancer, The UK, Sales Estimates ($m), 2002–2020
Table 11: Xeloda, Breast Cancer, France, Sales Estimates ($m), 2002–2020
Table 12: Xeloda, Breast Cancer, Germany, Sales Estimates ($m), 2002–2020
Table 13: Xeloda, Breast Cancer, Italy, Sales Estimates ($m), 2002–2020
Table 14: Xeloda, Breast Cancer, Spain, Sales Estimates ($m), 2002–2020
Table 15: Xeloda, Breast Cancer, Spain, Sales Estimates ($m), 2002–2020
1.2 List of Figures
Figure 1: Distribution by Incidence and Mortality, Most Commonly Diagnosed Cancers, Worldwide, 2010
Figure 2: Breast Cancer, Global, Market Size Forecasts ($bn), 2010–2020
Figure 3: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 4: Incidence per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 5: Breast Cancer, Incidence, Worldwide, 2008-2030
Figure 6: All Cancers, Incidence, Worldwide, 2008-2030
Figure 7: Mortality per 100,000, Breast Cancer, Selected Countries, 1975-2005
Figure 8: Breast Cancer, Mortality, Worldwide, 2008-2030
Figure 9: All Cancers, Mortality, Worldwide, 2008-2030
Figure 10: Broad Classification of Breast Cancer, By Type
Figure 11: Classification of Non-Invasive Breast Cancer, By CIS
Figure 12: Classification of Invasive Breast Cancer, By Stages
Figure 13: Classification of Invasive Breast Cancer, By Treatment
Figure 14: Current Molecular Biomarkers used in the Clinical Management of Breast Cancer
Figure 15: Breast Cancer Intrinsic Sub Types used for Deciding Treatment Options for MBC
Figure 16: Breast Cancer Types in Decreasing Order of their Aggressiveness
Figure 17: Treatment Options, DCIS Breast Cancer
Figure 18: Treatment Options, LCIS Breast Cancer
Figure 19: Classification of Stages I, II and IIIA
Figure 20: Treatment Options, Stages I, II and IIIA (HR Positive and Premenopausal Breast Cancer)
Figure 21: Treatment Options, Stages I, II and IIIA (HR Negative, Pre and Postmenopausal Breast Cancer)
Figure 22: Treatment Options, Stages I, II and IIIA (HR Positive Postmenopausal Breast Cancer)
Figure 23: Adjuvant Therapy for HR Positive, HER2 Negative Metastatic Breast Cancer
Figure 24: Hormonal Therapy in Adjuvant Setting in HR Positive, HER2 Negative MBC
Figure 25: Adjuvant and First Line Therapy for HR Negative, HER2 Negative Metastatic Breast Cancer
Figure 26: Treatment Options, HR Negative and HER2 Positive Metastatic Breast Cancer
Figure 27: Drug Model Diagram of Xeloda
Figure 28: Xeloda, Breast Cancer, Global, Sales Estimates ($m), 2002–2020
Figure 29: Xeloda, Breast Cancer, The US, Sales Estimates ($m), 2002–2020
Figure 30: Xeloda, Breast Cancer, The UK, Sales Estimates ($m), 2002–2020
Figure 31: Xeloda, Breast Cancer, France, Sales Estimates ($m), 2002–2020
Figure 32: Xeloda, Breast Cancer, Germany, Sales Estimates ($m), 2002–2020
Figure 33: Xeloda, Breast Cancer, Italy, Sales Estimates ($m), 2002–2020
Figure 34: Xeloda, Breast Cancer, Spain, Sales Estimates ($m), 2002–2020
Figure 35: Xeloda, Breast Cancer, Japan, Sales Estimates ($m), 2003-2020
Figure 36: Xeloda, Breast Cancer, Global, Sales Distribution by Country (%), 2020
Figure 37: Patients Approved for the Drug
Ordering:
Order Online - http://www.researchandmarkets.com/reports/2114425/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Page 1 of 2
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from
USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/
Order Information
Please verify that the product information is correct and select the format(s) you require.
Product Name:
Xeloda (Breast Cancer) - Analysis and Forecasts to 2020
Web Address:
http://www.researchandmarkets.com/reports/2114425/
Office Code:
SCHL3FA7
Product Formats
Please select the product formats and quantity you require:
Quantity
Electronic (PDF) Site License:
USD 4000
Electronic (PDF) Single User:
USD 2000
Electronic (PDF) Enterprisewide:
USD 6000
Contact Information
Please enter all the information below in BLOCK CAPITALS
Title:
First Name:
Mr
Mrs
Dr
Miss
Last Name:
Email Address: *
Job Title:
Organisation:
Address:
City:
Postal / Zip Code:
Country:
Phone Number:
Fax Number:
* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Ms
Prof
Page 2 of 2
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.
Pay by credit card:
You will receive an email with a link to a secure webpage to enter your
credit card details.
Pay by check:
Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.
Pay by wire transfer:
Please transfer funds to:
Account number
833 130 83
Sort code
98-53-30
Swift code
ULSBIE2D
IBAN number
IE78ULSB98533083313083
Bank Address
Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:
Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at
http://www.researchandmarkets.com/info/terms.asp
Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World